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Biochemical adrenal insufficiency induced by glucocorticoid treatment is prevalent, but data
on the clinical implications are sparse. We investigated clinical consequences of glucocorti-
coid-induced adrenal insufficiency after oral glucocorticoid cessation.
Methods
We conducted a Danish population-based self-controlled case series utilizing medical regis-
tries. In this design each individual serves as their own control allowing event rates to be
compared as a function of time and treatment. Clinical indicators of adrenal insufficiency
were defined as diagnoses of gastrointestinal symptoms, hypotension, cardiovascular col-
lapse, syncope, hyponatremia, and hypoglycaemia. We included 286,680 persons who dis-
continued long-term (� 3 months) oral glucocorticoid treatment. We defined five risk periods
and a reference period (before treatment): period 0 (on treatment), withdrawal period (1
month before and after cessation), followed by three consecutive 2 month-risk periods after
withdrawal (periods 2–4).
Results
Median age at cessation was 69 years and 57% were female. Median treatment duration
was 297 days and median cumulative dose was 3000 mg prednisolone equivalents. The
incidence rates of hypotension, gastrointestinal symptoms, hypoglycemia and hyponatre-
mia were increased in the withdrawal period compared to before treatment started (refer-
ence period). Incidence rate ratios comparing the withdrawal period with the reference
period were 2.5 [95% confidence interval (CI): 1.4–4.3] for hypotension, 1.7 (95% CI: 1.6–
1.9) for gastrointestinal symptoms, 2.2 (95% CI: 0.7–7.3) for hypoglycemia, and 1.5 (95%
CI: 1.1–2.0) for hyponatremia. During 7 months of follow up, the rates of hypotension and
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gastrointestinal symptoms remained elevated compared to the reference period. Risk fac-
tors included use of antibiotics, increasing average daily dose of glucocorticoids, cumulative
dose, and age.
Conclusion
Oral glucocorticoid withdrawal was associated with adverse outcomes attributable to adre-
nal insufficiency. Our study underscores the need for future research to establish evidence-
based clinical guidance on management of patients who discontinue oral glucocorticoids.
Introduction
Primary adrenal insufficiency and secondary adrenal insufficiency due to a pituitary disorder
are rare but serious conditions necessitating appropriate replacement therapy [1–3]. In con-
trast, adrenal insufficiency induced by pharmacological glucocorticoid treatment, i.e., iatro-
genic or tertiary adrenal insufficiency, is highly prevalent but the clinical implications are less
certain [4, 5].
Cortisol regulates an array of vital physiologic functions related to maintenance of basal
and stress-related homeostasis [6–8]. The cardiovascular response to stress depends on corti-
sol-mediated activation of adrenergic receptors [7]. Cortisol also acts in concert with glucagon,
catecholamines, and growth hormone to stimulate hepatic glucose output and lipolysis [7],
and exerts effects that dampen stress-induced inflammatory and immune responses [7].
Glucocorticoid treatment suppresses the hypothalamic-pituitary-adrenal (HPA) axis, which
may compromise endogenous cortisol secretion in response to stress and thus induce a state of
relative adrenal insufficiency [1, 2]. In addition, discontinuation of glucocorticoid treatment
can induce prolonged or even permanent suppression of endogenous cortisol secretion, as
assessed by biochemical stimulation tests [4, 9–15]. A recent meta-analysis estimated a 50%
pooled risk of biochemical adrenal insufficiency among oral glucocorticoid users [4]. This is
noteworthy, considering that the annual prevalence of systemic glucocorticoid use is 3% in the
Danish population [16]. Nonetheless, current knowledge regarding the clinical implications of
glucocorticoid-induced adrenal insufficiency is restricted to anecdotal reports of fatigue, mus-
cle weakness, gastrointestinal symptoms, hypotension, syncope, cardiovascular collapse, hypo-
natremia, and hypoglycemia [17–19]. The knowledge gap is reflected in current guidelines by
the lack of evidence-based recommendations about management of iatrogenic adrenal insuffi-
ciency [20, 21]. We therefore conducted a population-based self-controlled case series analysis
of clinical indicators of adrenal insufficiency during and after withdrawal of oral glucocorti-
coids. We defined putative clinical indicators of adrenal insufficiency and reported incidence
rates before and after withdrawal of glucocorticoid treatment. We then used a self-controlled
case series design [22, 23], in which each individual served as their own control and adverse
event rates during and after glucocorticoid treatment were compared to a reference period.
Material and methods
Setting
Denmark provides its entire population with tax-supported healthcare, guaranteeing access to
primary and secondary care free-of-charge. A unique personal civil registration number is
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assigned to all Danish residents at birth or upon immigration, enabling accurate and unambig-
uous individual-level linkage of relevant registries [24].
Study population
We used the Danish National Prescription Registry [25] (DNPR) to identify all persons who
discontinued long-term (� 3 months) treatment with oral glucocorticoids between January 1,
1996 and December 31, 2014 [26]. A flow chart of the study population is presented in Fig 1.
The DNPR records information on pharmacy customers’ civil registration number, the
redeemed medication’s classification code [Anatomical Therapeutic Chemical (ATC) classifi-
cation system of the World Health Organization], date of dispensing, the number of packages
dispensed, the number of tablets in a package, tablet strength, and amount dispensed,
expressed in terms of “defined daily doses” (DDDs) developed by WHO. Subjects with a prior
diagnosis of adrenal insufficiency, as well as subjects on continuous hydrocortisone treatment
indicative of adrenal insufficiency, were excluded (n = 4,272). ATC codes for glucocorticoids
and other relevant medications are provided in S1 Table.
Exposure
We defined an observation period ranging from 3 months before initiation of an oral gluco-
corticoid to 7 months after the date of the last glucocorticoid prescription (cessation) for each
person in the study population. The observation period was then divided into five risk periods
(Fig 2). The definition of observation period and risk periods were based on findings of bio-
chemical adrenal insufficiency in prior clinical studies [4, 5, 9–15]. Risk period 0 covered the
time from the date of glucocorticoid therapy initiation to 1 month before redemption of the
last glucocorticoid prescription. Risk period 1 (withdrawal period) covered the time from 1
month before redemption of the last prescription for a glucocorticoid to 1 month after this
redemption (Days -30 to day 29). Risk period 2 covered months 2–3 after redemption of the
last glucocorticoid prescription (Days 30 to 89); risk period 3 covered months 4–5 after
redemption of the last glucocorticoid prescription (Days 90 to 149), and risk period 4 corre-
sponded to months 6–7 after redemption of the last prescription (Days 150 to 210). Finally, the
reference period was defined as months 3 and 2 before the date of oral glucocorticoid
initiation.
Clinical indicators
The following putative clinical indicators of adrenal insufficiency were identified in the Danish
National Patient Registry (DNPR): hypotension, syncope, cardiovascular collapse, hyponatre-
mia, hypoglycemia, and gastrointestinal symptoms [1]. Among persons with gastrointestinal
symptoms, we excluded those with inflammatory bowel disease (IBD) from the analyses. Per-
sons receiving insulin or sulfonylurea treatment were excluded from the hypoglycemia
analyses.
Only primary inpatient diagnoses were included to obtain the most accurate date of diagno-
sis. An exception was syncope; for this indicator, emergency department visits were included
in addition to inpatient diagnoses, as medical assessment of this condition usually occurs in
the emergency setting. The DNPR has tracked all inpatient stays at Danish public hospitals
since 1977, and outpatient clinic and emergency room visits at all public hospitals since 1995.
Data recorded in the DNPR include the patient’s civil registration number, dates of admission
and discharge or outpatient visit dates, discharge diagnoses for each contact, classified accord-
ing to the Eighth Revision of the International Classification of Diseases (ICD-8) until 1994 and
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Fig 1. Flow chart of the study population. � The observation period ranges from 3 months before initiation of first long-term (� 3 months) oral
glucocorticoid treatment to 7 months after the date of last glucocorticoid prescription (cessation).
https://doi.org/10.1371/journal.pone.0212259.g001
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the Tenth Revision thereafter (ICD-10) [27]. The ICD codes used in this study are provided in
S2 Table.
Statistical analysis
We characterized our study population according to type of last glucocorticoid prescription,
duration of treatment (median, IQR), cumulative dose in prednisolone equivalents (median,
IQR), average daily dose in prednisolone equivalents, and according to age, sex, morbidity,
and concomitant treatment with inhaled, topical or injectable glucocorticoids and glucocorti-
coids acting on the intestine. The codes for morbidity are provided in S3 Table. Calculations
for prednisolone-equivalent cumulative doses are provided in S4 Table.
Based on the entire study population of persons who discontinued oral glucocorticoid treat-
ment, we calculated incidence rates and 2-week prevalence. We estimated incidence rates in
the reference period and the five risk periods. Each type of clinical indicator was analysed sepa-
rately and persons were followed from start of the period of interest until first event, emigra-
tion, death or end of the period of interest, whichever came first. We calculated and presented
graphically the 2-week prevalence during the period of 12 months before to 7 months after
redemption of the last glucocorticoid prescription.
Self -controlled case series design. We estimated incidence rate ratios (IRRs) using the
self-controlled case series design [22, 28]. This design is a case-only design and each case serves




PLOS ONE | https://doi.org/10.1371/journal.pone.0212259 February 19, 2019 5 / 15
as their own control. Thus, the method inherently accounts for confounding factors that are
stable over time (e.g., sex, ethnicity and genetics). First, we identified cases in the observation
period (Fig 2). We analysed each type of clinical indicator as a distinct case variable. In addi-
tion, we only considered the first event (e.g. recurrent events were not included in the analy-
ses). This is the recommended approach by Petersen et al., when recurrent events cannot be
assumed independent [22]. Second, we used a conditional fixed-effect Poisson regression to
compare incidence rates in the pre-defined risk periods with the incidence rate in the reference
period. The follow-up time was not censored at an event. Hence, all time occurring within the
observation period (both before and after individuals have experienced the event) was
included in the analysis. Nevertheless, individuals were censored at the end of the observation
period or death, whichever came first.
In a sub-analysis we stratified on cumulative glucocorticoid dose (< 0.5 g, 0.5–5 g, >5g).
Risk factors for adrenal insufficiency. We used Cox proportional hazard regression to
identify potential risk factors, such as sex, age (< 30, 30–49, 50–69, and� 70 years of age),
treatment duration (< 6 months, 6–12 months, 1–2 years, and> 2 years), cumulative treat-
ment dose (< 0.5 gram (g), 0.5–5 g,> 5 g expressed in prednisolone equivalents), average
daily dose (< 5 mg/day, 5–9 mg/day, 10–20 mg/day and> 20 mg/day expressed in predniso-
lone equivalents), and use of antibiotics. As infections are major precipitating causes of adrenal
crisis, we assessed use of antibiotics as a proxy for infection. Antibiotic use was modelled as a
time-varying exposure and a person was counted as exposed 30 days after a prescription
redemption. We followed our study population from date of cessation until a diagnosis of a
clinical indicator (only those indicators showing increased risk during or after withdrawal),
death, emigration or end of the observation period, whichever came first. The assumption of
proportional hazards was verified graphically.
Sensitivity analyses. We conducted several sensitivity analyses to ensure the validity of
our results. First, we addressed the concern that if an event increases the probability of death,
then the observation periods could be shortened as a direct result of the event. This event-
dependent censoring can lead to bias in the self-controlled case series design [22]. Therefore,
in a sensitivity analysis we excluded persons who died 60 days after an event. Any major differ-
ences in the results of the sensitivity analysis compared to our main results would suggest bias.
Second, as the self-controlled case series design can be sensitive to changes in health care utili-
zation, a negative outcome analysis was conducted using erysipelas as outcome. Erysipelas is
assumed to be unrelated to both adrenal insufficiency and the condition for which glucocorti-
coid was prescribed. Third, since alternative routes of glucocorticoid administration (i.e.,
injection, inhalation, topical, or glucocorticoids acting on the intestine) also may induce adre-
nal insufficiency, concomitant use of these types of glucocorticoids could potentially affect our
results. To control for this factor, we conducted a sensitivity analysis restricted to persons
treated only with oral glucocorticoids.
All statistical analyses were conducted using Stata 14 for Windows.
This study was approved by the Danish Data Protection Agency (Record number: 2016-
051-000001, serial number 448). According to Danish legislation, informed consent or
approval from an ethical committee is not required for registry based studies.
Results
In total, we identified 286,680 persons who discontinued long-term (� 3 months) oral gluco-
corticoid treatment (Fig 1). The most frequent type of last redeemed prescription was prednis-
olone [n = 280,010 (98%)] (Table 1). Median treatment duration was 297 days [interquartile
range (IQR): 179–584 days]; median cumulative dose was 3000 mg prednisolone equivalents
Iatrogenic adrenal insufficiency
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Table 1. Characteristics of 286,680 oral glucocorticoid users according to sex, age, glucocorticoid type, dose, and



















< 0.5 g 21,114 (7.4)
0.5–5 g 171,566 (60)
5+ g 94,000 (33)
Average daily dose a
< 5 mg /day 86,099 (30)
5–9 mg/day 114,194 (40)
10–20 mg/day 57,970 (20)
20 + mg/day 28,417 (9.9)
Morbidity
Polymyalgia rheumatica/ giant cell arteritis 28,220 (9.8)
Rheumatoid arthritis 21,256 (7.4)
Psoriasis arthritis 1,943 (0.68)
Ankylosing spondylitis 881 (0.31)
Other rheumatological diseases 9,129 (3.2)
Other autoimmune diseases 1,900 (0.66)
Renal diseases 12,568 (4.4)
Cancer 64,503 (23)
Dermatological diseases 1,851 (0.65)
Ulcerative colitis 10,841 (3.8)
Crohn’s disease 6,264 (2.2)
Ashma 29,573 (10)
COPD 63,685 (22)
Multiple sclerosis 1,656 (0.58)
Concomitant glucocorticoid treatmentb
Locally acting (inhaled, acting on the intestine, or topical) 90,937 (32)
Injections 15,971 (5.6)
a In prednisolone equivalents.
b Defined as prescription redemption throughout the observation period.
https://doi.org/10.1371/journal.pone.0212259.t001
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(IQR: 1,125–6,500 mg), and median average daily dose was 6.8 mg prednisolone equivalents
per day (IQR: 4.6–12 mg per day). Median age at cessation was 69 years (IQR: 57–78 years)
and 163,077 (57%) were female (Table 1). Inhaled glucocorticoids, topical or glucocorticoids
acting on the intestine were used concomitantly by 90,937 persons (32%), and 15,971 persons
(5.6%) received glucocorticoid injections (Table 1). Morbidities frequently recorded at any
time prior to glucocorticoid cessation included cancer [64,503 (23%)], COPD [63,685 (22%)],
asthma [29,573 (10%)], polymyalgia rheumatica/giant cell arteritis [28,220 (9.8%)], and rheu-
matoid arthritis [21,256 (7.4%)] (Table 1).
In total, 10,963 incident cases of clinical indicators were identified in the observation period
(hypotension: 295 cases; syncope: 3,568 cases; cardiovascular collapse: 96 cases; gastrointestinal
symptoms: 6,332 cases; hyponatremia: 634 cases; hypoglycemia: 38 cases) (Fig 1). Only 49 per-
sons were coded with treatment-induced adrenal insufficiency during the observation period.
Compared to the reference period, the incidence rates of gastrointestinal symptoms, hypoten-
sion, cardiovascular collapse, hyponatremia, and hypoglycemia were all elevated in risk period 1
(the withdrawal period) and in risk period 2 (except for hyponatremia). The incidence rate of
gastrointestinal symptoms increased to a maximum of 30 per 1000 person-years (P-Y) [95%
confidence interval (CI): 28–31 per 1000 P-Y] in risk period 1 (withdrawal period), and
remained elevated in risk period 2 with an incidence rate of 24 per 1000 P-Y (95% CI: 22–36 per
1000 P-Y) (Table 2). The incidence rate of hyponatremia was 2.4 per 1000 P-Y (95% CI: 2.0–2.9
per 1000 P-Y) in risk period 1 (Table 2). The incidence rate of hypotension was 0.9 per 1000 P-Y
(95% CI: 0.7–1.2 per 1000 P-Y) in risk period 1 and 0.7 per 1000 P-Y (95% CI: 0.5–1.1 per 1000
P-Y) in risk period 2 (Table 2). The incidence rate of hypoglycemia was 0.2 per 1000 P-Y (95%
CI: 0.1–0.4 per 1000 P-Y) in risk period 1 and 0.3 per 1000 P-Y (95% CI: 0.1–0.7 per 1000 P-Y)
in risk period 2 (Table 2). No diagnoses of cardiovascular collapse occurred in the reference
period, but incidence rates in risk periods 1 and 2 were 0.5 per 1000 P-Y (95% CI: 0.3–0.7 per
1000 P-Y) and 0.6 per 1000 P-Y (95% CI: 0.4–0.9 per 1000 P-Y), respectively (Table 2).
Fig 3 presents the 2-week prevalence of all clinical indicators of adrenal insufficiency (gas-
trointestinal symptoms, hypotension, cardiovascular collapse, hyponatremia, hypoglycemia,
syncope), and the negative outcome (erysipelas). The prevalence of a composite of all clinical
indicators increased to a maximum of 2.6 per 1000 in the 2 weeks after the last glucocorticoid
prescription and remained higher than before discontinuation during 1.5 months following
the last prescription. Gastrointestinal symptoms had the highest prevalence, with a maximum
of 1.8 events per 1000 in the 2 weeks after the last prescription redemption.
The distribution of the total number of admissions per person during risk periods 0–4 is
presented in S5 Table.
Table 2. Incidence rates per 1000 person-years with 95% confidence intervals (CI) (n = 286,680).
Incidence rates per 1000 person years with 95% CIs
Reference period Risk period 0 Risk period 1
(withdrawal period)
Risk period 2 Risk period 3 Risk period 4
Hypotension 0.4 (0.3–0.6) 0.5 (0.5–0.6) 0.9 (0.7–1.2) 0.7 (0.5–1.1) 0.5 (0.3–0.8) 0.4 (0.2–0.7)
Syncope 8.8 (8.0–9.7) 6.1 (5.8–6.3) 8.6 (7.8–9.5) 0.7 (6.6–8.3) 6.7 (5.9–7.6) 5.6 (4.8–6.6)
Cardiovascular collapse NA NA 0.5 (0.3–0.7) 0.6 (0.4–0.9) NA NA
Hyponatremia 1.7 (1.4–2.1) 0.9 (0.8–1.0) 2.4 (2.0–2.9) 1.4 (1.1–1.9) 1.1 (0.8–1.6) 0.8 (0.5–1.2)
Gastrointestinal symptoms 19 (18–21) 14 (13–14) 30 (28–31) 24 (22–36) 15 (13–16) 14 (12–15)
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Self-controlled case series design
The incidence rates of hypotension, gastrointestinal symptoms, hypoglycemia and hyponatre-
mia were increased in the withdrawal period compared to before treatment started (reference
period). The IRRs were 2.5 (95% CI: 1.4–4.3) for hypotension, 1.7 (95% CI: 1.6–1.9) for gastro-
intestinal symptoms, 2.2 (95% CI: 0.7–7.3) for hypoglycemia, and 1.5 (95% CI: 1.1–2.0) for
hyponatremia (Table 3). The risk of hypotension, gastrointestinal symptoms, and hypoglyce-
mia remained elevated, although at a declining rate, during the 7 months of follow up
(Table 3). The results of our sensitivity analyses showed that our estimates were robust (S6 and
S7 Tables), although the IRRs for hyponatremia attenuated after exclusion of persons with
concomitant use of other glucocorticoids (i.e., those administered by injection, topical, or
inhalation, or glucocorticoids acting on the intestine) (S7 Table). No incident cases of cardio-
vascular collapse were identified in the reference period, so IRRs could not be computed. Our
negative outcome (erysipelas) revealed IRRs close to one (Table 3). The results, when stratify-
ing on cumulative glucocorticoid dose, are shown in S8 Table.
Risk factors
Risk factors for clinical indicators of adrenal insufficiency were use of antibiotics, increasing
average daily dose, increasing cumulative dose, and increasing age (Table 4).
Discussion
Our main finding were (1) the risks of hypotension, gastrointestinal symptoms, hyponatremia,
and hypoglycemia in the glucocorticoid withdrawal period were increased compared to before
starting glucocorticoid treatment and remained elevated for hypotension and gastrointestinal
symptoms during 7 months of follow up, (2) use of antibiotics, cumulative dose of oral gluco-
corticoids, average daily dose, and age were associated with increased risk of clinical indicators
of adrenal insufficiency during and after withdrawal of glucocorticoid therapy.
To the best of our knowledge, this study is the first to systematically investigate the clinical
impact of adrenal insufficiency following oral glucocorticoid withdrawal and it extends anec-
dotal reports in the literature [17–19]. Prior randomized controlled trials [9, 10] (range:
n = 10–42 included persons) and cohort studies [11–15] (range: n = 10–150 persons included)
Fig 3. The 2-week prevalence (per 1000 persons) of clinical indicators of adrenal insufficiency and the negative outcome during the period of 12 month before
the last glucocorticoid prescription to 7 months after this prescription. (a) All clinical indicators. (b) Gastrointestinal symptoms. (c) Hypotension. (d)
Cardiovascular collapse. (e) Hyponatremia. (f) Hypoglycemia. (g) Syncope. (h) Negative outcome.
https://doi.org/10.1371/journal.pone.0212259.g003
Table 3. Incidence rate ratios (IRRs) with 95% confidence intervals (CIs) for events by risk period.
IRR and (95% CI)
Syncope Hypo-
natremia
Hypotension Gastrointestinal symptoms Hypoglycemia Negative outcome
(erysipelas)
Number of cases 3,568 634 295 6,332 38 1,850
Reference period 1 1 1 1 1 1
Risk period 0 0.8 (0.7–0.9) 0.7 (0.6–1.0) 1.5 (0.9–2.5) 1.0 (0.9–1.1) 0.6 (0.2–2.1) 1.0 (0.8–1.2)
Risk period 1 1.1 (0.9–1.2) 1.5 (1.1–2.0) 2.5 (1.4–4.3) 1.7 (1.6–1.9) 2.2 (0.7–7.3) 1.1 (0.9–1.4)
Risk period 2 1.0 (0.9–1.2) 1.1 (0.7–1.5) 2.3 (1.3–4.3) 2.0 (1.8–2.2) 2.4 (0.6–9.5) 1.0 (0.8–1.3)
Risk period 3 1.0 (0.8–1.2) 0.9 (0.6–1.4) 2.0 (1.0–3.9) 1.5 (1.3–1.7) NA 1.1 (0.9–1.5)
Risk period 4 0.9 (0.7–1.0) 0.7 (0.4–1.1) 1.7 (0.8–3.6) 1.5 (1.3–1.7) 0.9 (0.1–8.9) 1.1 (0.8–1.4)
https://doi.org/10.1371/journal.pone.0212259.t003
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have been unable to establish a time course for adrenal recovery after glucocorticoid cessation.
The systematic review by Joseph et al. reported a percentage range for biochemical adrenal
insufficiency of 27%-69% in patients tested more than 30 days after their last glucocorticoid
dose [5]. Our findings suggest that symptomatic adrenal insufficiency peaks up to 3 months
after cessation of treatment and remains increased for at least 7 months. Previous studies have
debated the association between dose and duration of glucocorticoid treatment and iatrogenic
biochemical adrenal insufficiency. In general, high dose and longer treatment duration have
been associated with higher adrenal insufficiency risk [4, 5]. Our study confirmed that gluco-
corticoid dose is a risk factor for clinical adrenal insufficiency. In addition, persons exposed to
an infection (potential stressor) were also at increased risk of clinical adrenal insufficiency,
which fits well with the underlying pathophysiology of cortisol deficiency [7]. Our study has
several strengths. The nationwide population-based design allowed us to assess clinical indica-
tors of adrenal insufficiency in a large heterogeneous population representative of clinical
practice. Further, using the self-controlled case series analysis, we were able to take into
account patient characteristics that are stable over time, including potential unmeasured or
unknown confounders (i.e. sex, genetics and lifestyle).
Our study also has limitations. First, we used prescription redemption as a proxy for use.
Thus, we were unable to assess adherence or to include inpatient hospital medication use.
Table 4. Risk factors for clinical indicators of adrenal insufficiency.









Average daily dose in prednisolone equivalents
< 5 mg /day 1
5–9 mg/day 1.13 (1.02–1.25)
10–20 mg/day 1.76 (1.59–1.94)
20 + mg/day 3.28 (2.89–3.73)
Treatment duration
< 6 months 1
6–12 months 1.12 (1.01–1.24)
1–2 years 1.03 (0.92–1.16)
> 2 years 1.21 (1.07–1.36)
Cumulative dose in prednisolone equivalents
< 0.5 g 1
0.5-5g 1.25 (1.10–1.41)




a Proxy for infection. The antibiotic prescription had to be redeemed up to 30 days prior to an event to count as a
precipitating factor (modelled as a time-varying exposure)
https://doi.org/10.1371/journal.pone.0212259.t004
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Moreover, we were unable to ascertain the exact timing of the last glucocorticoid dose. It is
likely that patients tapered their glucocorticoid therapy for weeks after redemption of their last
prescription. To accommodate these inaccuracies, we defined the withdrawal period as a
2-month period encompassing the redemption date of the last prescription. Use of wide risk
periods may have biased the IRR estimates toward the null. In addition, we were unable to
investigate different tapering schedules.
Second, although the self-controlled case series design accounts for time-independent con-
founders, it remains sensitive to changes over time in such factors as morbidity or health care
utilization. Therefore, confounding by indication or disease severity could affect some of our
IRR estimates. For example, gastrointestinal symptoms may be related to IBD relapse. To over-
come this, we excluded IBD patients in the assessment of gastrointestinal symptoms. Con-
founding by use of insulin and sulfonylurea, also were eliminated by exclusion. It is well
known that use of other glucocorticoid formulations, such as inhaled and injectable forms and
glucocorticoids acting on the intestine, also increases the risk of iatrogenic adrenal insuffi-
ciency [29, 30]. In our study, 32% of patients used locally acting glucocorticoids (inhaled, topi-
cal, or glucocorticoids acting on the intestine) and 5.6% of patients were treated with
glucocorticoid injections in addition to oral glucocorticoids. However, our sensitivity analysis
excluding persons with concomitant glucocorticoid treatment did not affect our estimates sub-
stantially. We found no association between discontinuation and erysipelas (our negative out-
come) indicating that changes in health care utilization were not a major issue.
Third, the self-controlled case series analysis can be sensitive to reverse causation. We did
not expect that any of the outcome events would change the decision to prescribe glucocorti-
coids. However, a change in exposure status from continuous user to discontinued user may
be correlated to the terminal phase of illness. Therefore, we were not able to assess death as an
outcome. In addition, in the terminal phase, morbidity and frequency of hospitalization often
increase, which could potentially lead to incorrect associations. Nevertheless, excluding per-
sons who died 60 days after an event did not alter our results, indicating this was not a major
issue in our study.
Fourth, our use of hospital registry data to assess outcomes raises the possibility of misclas-
sification. Hyponatremia and cardiovascular collapse diagnoses have been validated and the
positive predictive values are> 90%, however, other outcomes used in our study lack valida-
tion [27]. Still, misclassification of outcomes is unlikely to vary systematically according to ref-
erence and risk periods. Thus, it could not explain any associations found in the self-
controlled case series analysis. Another concern is that low data completeness could lead to
underestimation of our incidence rates and 2-week prevalence. Furthermore, the defined clini-
cal indicators are not specific for adrenal insufficiency. In addition, we were only able to assess
outcomes that led to a hospital contact. Hence, less severe indicators, such as fatigue and mus-
cle weakness, were not captured. We also lacked access to biochemical data, hence cortisol
measurements could not be assessed. Finally, only 49 persons in our study had a recorded
diagnosis of treatment-induced adrenal insufficiency. This small number most likely reflects
lack of awareness and failure to diagnose iatrogenic adrenal insufficiency, considering that dis-
continuation of glucocorticoids may induce biochemical adrenal insufficiency in 50% of
patients [4].
In conclusion, we found that oral glucocorticoid withdrawal was associated with observable
clinical outcomes attributable to adrenal insufficiency, although the incidence rates were low.
Our study underscores the importance for future research to establish evidence-based clinical
guidance on procedures for patients’ withdrawal from glucocorticoid use, as well as guidance
for identifying patients in need of biochemical testing.
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